Lee, 2013 [14] | 242 | RCTs, placebo arms | Time-fixed at enrolment: anti-acid therapy versus non-use | 0.61 (0.33–1.14)¶ | 30 weeks |
Ekström, 2016 [19] | 462 | Cohort study: population-based, oxygen-dependent IPF | Time-dependent: anti-acid therapy versus non-use | 1.12 (0.87–1.42) | 4 years |
Kreuter, 2016 [20] | 272 | Cohort study: single centre | Time-fixed at baseline: PPI use versus non-use | 0.88 (0.42–1.83)¶ | 8 years |
Kreuter, 2016 [21] | 624 | RCTs, placebo arms | Time-fixed at enrolment: anti-acid therapy versus non-use | 0.80 (0.30–1.70) | 1 year |
Kreuter, 2017 [23] | 623 | RCTs, treatment arms | Time-fixed at enrolment: anti-acid therapy versus non-use | 0.80 (0.30–2.50) | 1 year |